Genmab A-S

Затворен

1,871 4.26

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1794.5

Максимум

1876

Ключови измерители

By Trading Economics

Приходи

21M

52M

Продажби

-184M

881M

P/E

Средно за сектора

21.339

56.269

EPS

8.48

Марж на печалбата

5.915

Служители

3,088

EBITDA

-30M

215M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-1.49% downside

Дивиденти

By Acuity

Следващи печалби

6.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

8.4B

113B

Предишно отваряне

1866.74

Предишно затваряне

1871

Genmab A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.07.2026 г., 23:56 ч. UTC

ETF Constituents
Macro News

American Water Works seeks $179 million in new rates, boosting investor sentiment for utilities. Utilities Select Sector SPDR Fund trades higher in after-market hours.

1.07.2026 г., 23:56 ч. UTC

Intuitive Surgical Inc. shares are trading roughly flat in after-market hours, reflecting routine performance amid a slight decline from its 20-day moving average.

1.07.2026 г., 23:56 ч. UTC

Sirius XM Holdings Inc. shares are lower in after-market hours amid broader market caution from U.S.-Iran peace talks and mixed central bank signals.

1.07.2026 г., 23:52 ч. UTC

News
Correlated Moves
Social Media

Meta Platforms Inc. shares fell in after-market trading amid a broader tech market downturn, despite earlier gains on plans for a cloud computing business.

1.07.2026 г., 23:52 ч. UTC

Brazil's Retail Sales Report on July 8, 2026, Expected Amid Mixed Sentiment Following Recent Manufacturing Growth.

1.07.2026 г., 23:52 ч. UTC

South Korea's June inflation rate rises to 3.2%, matching forecasts amid concerns over rising costs from geopolitical tensions and potential interest rate tightening.

1.07.2026 г., 23:52 ч. UTC

US Factory Orders Expected to Contract by 1.8% in May Amid Mixed Manufacturing Data and Inflation Concerns

1.07.2026 г., 23:51 ч. UTC

Social Media
News
Correlated Moves
ETF Constituents

Invesco QQQ Trust trading lower after Nasdaq 100 decline, reflecting a market shift away from technology stocks. Notable trades occurred at $737.25.

1.07.2026 г., 23:51 ч. UTC

Correlated Moves

NVIDIA Corp is trading lower in after-market hours, influenced by a broader market decline and volatility among large-cap stocks.

1.07.2026 г., 23:51 ч. UTC

Global equity markets show mixed performance amid geopolitical tensions, with U.S. economic data revealing weaker-than-expected manufacturing growth and job gains, while Eurozone inflation declines raise hopes for potential ECB policy shifts.

1.07.2026 г., 23:51 ч. UTC

Asia equity markets rise amid geopolitical tensions, while U.S. indices dip as inflation concerns loom and Fed signals rate hike; Bitcoin gains 2.4%.

1.07.2026 г., 23:51 ч. UTC

US equity indices decline amid geopolitical tensions and central bank discussions, while Bitcoin rises; Barclays warns of vulnerabilities in U.S. markets as focus shifts to Fed Chair's upcoming remarks on inflation.

1.07.2026 г., 23:51 ч. UTC

Mixed trading in European equity markets amid declining Eurozone inflation and cautious investor sentiment ahead of central bank speeches.

1.07.2026 г., 23:51 ч. UTC

JD.Com Inc shares are lower in after-market hours amid broader market declines. No specific company news was identified to explain the movement.

1.07.2026 г., 23:51 ч. UTC

Social Media
Correlated Moves
ETF Constituents

SPDR S&P 500 ETF Trust declines after hours, influenced by slight losses in major holdings like NVIDIA and Tesla amid concerns over AI stock valuations.

1.07.2026 г., 23:51 ч. UTC

ETF Constituents

SPDR S&P Regional Banking ETF rises in after-hours trading, rebounding from earlier lows. CFFN contributed significantly with a 1.85% return.

1.07.2026 г., 23:51 ч. UTC

NetApp Inc shares are lower in after-market trading, reflecting broader market declines. The asset remains below its 20-day moving average amid routine fluctuations.

1.07.2026 г., 23:51 ч. UTC

Social Media
ETF Constituents
Macro News

iShares MSCI South Korea ETF advances after-market hours, despite KOSPI losses and rising inflation concerns impacting investor sentiment. Volatility remains high around the asset.

1.07.2026 г., 23:51 ч. UTC

Correlated Moves
Social Media

Micron Technology Inc. shares are lower in after-market trading amid broader market declines. The company forecasts $41.5 billion in revenue by May 2026.

1.07.2026 г., 23:46 ч. UTC

Paychex Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader investor caution may be influencing market sentiment.

1.07.2026 г., 23:46 ч. UTC

KLA Corp shares are higher in after-market trading, reflecting strong momentum since Wednesday's close, with the price above its 20-day moving average.

1.07.2026 г., 23:46 ч. UTC

Social Media

Comcast Corp trades slightly above its pre-announcement price amid social media discussions contrasting Peacock's performance with Xumo and mentions of competitors in the sector.

1.07.2026 г., 23:42 ч. UTC

Mortgage Rates Dip to 6.57% Amid Mixed Signals in U.S. Mortgage Applications and Economic Uncertainty

1.07.2026 г., 23:42 ч. UTC

Social Media
Correlated Moves

Applied Materials Inc is gaining in after-market trading, supported by a rise in Taiwan Semiconductor Manufacturing and continued social media interest.

1.07.2026 г., 23:41 ч. UTC

Netflix Inc. shares advanced modestly in after-market trading, despite remaining below their 20-day moving average and near the lower end of their one-month range.

1.07.2026 г., 23:41 ч. UTC

Marriott International Inc shares are rising in after-market trading, recovering from earlier lows and reflecting positive market sentiment. No specific news was identified.

1.07.2026 г., 23:41 ч. UTC

PayPal Holdings Inc. shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock is above its 20-day moving average.

1.07.2026 г., 23:41 ч. UTC

Correlated Moves
ETF Constituents

The Consumer Discretionary Select Sector SPDR Fund is higher in after-market hours, supported by gains from Amazon and Marriott, among other contributors.

1.07.2026 г., 23:41 ч. UTC

Correlated Moves
Macro News

Bitcoin is higher Wednesday, supported by Ethereum's rise, despite losing over 26,000 millionaire addresses this year amid 'Extreme Fear' in the market.

1.07.2026 г., 23:36 ч. UTC

Correlated Moves
News

Ethereum is trading higher, buoyed by Bitcoin's recent gains. Earlier in the session, Ethereum peaked before pulling back slightly but has since regained ground.

Сравнение с други в отрасъла

Ценова промяна

Genmab A-S Прогноза

Ценова цел

By TipRanks

-1.49% надолу

12-месечна прогноза

Среден 2,493.35 DKK  -1.49%

Висок 3,320 DKK

Нисък 308.417 DKK

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Genmab A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

3

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat